FDA orphan status awarded to Omeros' thrombotic microangiopathy drug

The FDA has granted orphan-drug status to Omeros' experimental antibody drug OMS721 as a treatment for complement-mediated thrombotic microangiopathies, which can cause clotting in the body's organs. A Phase I trial is underway to determine the drug's safety and pharmacokinetics. Omeros plans to conduct a midstage trial early next year to assess the drug's efficacy in preventing complement-mediated thrombotic microangiopathies.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC